Načítá se...
Landmark Studies Impacting the Medical Management of Benign Prostatic Hyperplasia
The treatment of benign prostatic hyperplasia (BPH) has changed dramatically over the past 10 years. Phase 3 studies of the safety and effectiveness of α-blockers (eg, terazosin and doxazosin) and 5-α-reductase inhibitors (eg, finasteride) for the treatment of BPH began to appear in the literature i...
Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MedReviews, LLC
2003
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1502363/ https://ncbi.nlm.nih.gov/pubmed/16985967 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|